

**Pharmacy Prior Approval Request for  
GLP-1's for Weight Management**

**Beneficiary Information**

1. Beneficiary Last Name: \_\_\_\_\_ 2. First Name: \_\_\_\_\_  
3. Beneficiary ID #: \_\_\_\_\_ 4. Beneficiary Date of Birth: \_\_\_\_\_ 5. Beneficiary Gender: \_\_\_\_\_

**Prescriber Information**

6. Prescribing Provider NPI #: \_\_\_\_\_  
7. Requester Contact Information - Name: \_\_\_\_\_ Phone #: \_\_\_\_\_ Ext. \_\_\_\_\_

**Drug Information**

8. Drug Name: \_\_\_\_\_ 9. Strength: \_\_\_\_\_  
10. Quantity Per 30 Days: \_\_\_\_\_  
11. Length of Therapy (in days):  up to 30 days  60 Days  90 Days  120 Days  180 Days  365 Days  Other \_\_\_\_\_

**Clinical Information**

**Initial Request (Wegovy, Saxenda, and Zepbound):**

1. Please list the beneficiary's baseline weight and BMI. Weight \_\_\_\_\_ Date \_\_\_\_\_ BMI \_\_\_\_\_ Date \_\_\_\_\_
2. Is the beneficiary 18 years of age or older?  **Yes**  **No**
  - 2a. Does the beneficiary have a BMI greater than or equal to 30 kg/m<sup>2</sup>?  **Yes**  **No**
  - 2b. Does the beneficiary have a BMI greater than or equal to 27 kg/m<sup>2</sup>?  **Yes**  **No**
  - 2b-i. Does the beneficiary have at least one weight-related comorbidity/risk factor/complication (i.e. hypertension, type 2 diabetes, obstructive sleep apnea, cardiovascular disease, dyslipidemia)?  **Yes**  **No List** \_\_\_\_\_
3. Is the beneficiary between 12-17 years of age?  **Yes**  **No**
  - 3a. Does the beneficiary have a BMI greater than or equal to the 95<sup>th</sup> percentile for age and sex?  **Yes**  **No**
  - 3b. Does the beneficiary have a BMI greater than or equal to 30 kg/m<sup>2</sup>?  **Yes**  **No**
  - 3c. Does the beneficiary have a BMI greater than or equal to the 85<sup>th</sup> percentile for age and sex?  **Yes**  **No**
  - 3c-i. Does the beneficiary have at least one weight-related comorbidity/risk factor/complication (i.e. hypertension, type 2 diabetes, obstructive sleep apnea, cardiovascular disease, dyslipidemia)?  **Yes**  **No List** \_\_\_\_\_
4. Is the beneficiary age 45 years of age or older?  **Yes**  **No**
  - 4a. Does the beneficiary have a BMI greater than or equal to 27 kg/m<sup>2</sup>?  **Yes**  **No**
  - 4a-i. Does the beneficiary have established cardiovascular disease (CVD) defined as having a history of myocardial infarction, stroke, or symptomatic peripheral disease?  **Yes**  **No List** \_\_\_\_\_
5. Is the beneficiary currently on and will the beneficiary continue lifestyle modification including structured nutrition and physical activity, unless physical activity is not clinically appropriate at the time GLP1 therapy commences?  **Yes**  **No**
6. Will the beneficiary be using the requested agent with another GLP-1?  **Yes**  **No**
7. Does the beneficiary have any FDA-labeled contraindications to the requested agent, including pregnancy, lactation, history of medullary thyroid cancer or multiple endocrine neoplasia type II?  **Yes**  **No**

**Continuation Request (Wegovy, Saxenda, and Zepbound):**

8. Has the beneficiary previously been approved for the requested agent through NC Medicaid's PA process?  **Yes**  **No**
9. Beneficiary's baseline and current weight. Baseline Wt. \_\_\_\_\_ Date \_\_\_\_\_ Current Weight \_\_\_\_\_ Date \_\_\_\_\_
10. Beneficiary's baseline and current BMI. Baseline BMI \_\_\_\_\_ Date \_\_\_\_\_ Current BMI \_\_\_\_\_ Date \_\_\_\_\_
11. Is the beneficiary continuing a current weight loss course of therapy?  **Yes**  **No**
12. **Ages 18 and older-** Has the beneficiary lost a total of 5% of pretreatment weight and is maintaining the 5% weight loss?  
 **Yes**  **No** Baseline Weight \_\_\_\_\_ Current Weight \_\_\_\_\_
13. **Ages (>12 to <18 years)** – Has the beneficiary lost a total >4% reduction in baseline BMI and is maintaining the weight loss?  
 **Yes**  **No** Baseline Weight \_\_\_\_\_ Current Weight \_\_\_\_\_

**Pharmacy Prior Approval Request for  
GLP-1's for Weight Management**

14. Does the beneficiary have a documented weight loss that is deemed to be a significant reduction from BMI per the prescriber and the weight loss is maintained, yet the 5% (for adults) and 4% (for adolescents) is not met?  **Yes**  **No**

Rationale \_\_\_\_\_

15. Is the beneficiary currently on and will continue lifestyle modification including structured nutrition and physical activity?

**Yes**  **No**

16. Will the beneficiary be using the requested agent with another GLP-1?  **Yes**  **No**

17. Does the beneficiary have any FDA-labeled contraindications to the requested agent, including pregnancy, lactation, history of medullary thyroid cancer or multiple endocrine neoplasia type II?  **Yes**  **No**

**Request for Non-Preferred Drug (Saxenda, and Zepbound):**

1. Failed preferred drug(s). List preferred drugs failed: \_\_\_\_\_

1a.  Allergic Reaction 1b.  Drug-to-drug interaction. Please describe reaction: \_\_\_\_\_

2. Previous episode of an unacceptable side effect or therapeutic failure. Please provide clinical information:  
\_\_\_\_\_  
\_\_\_\_\_

3. Clinical contraindication, co-morbidity, or unique patient circumstance as a contraindication to preferred drug(s). Please provide clinical information: \_\_\_\_\_

4. Age specific indications. Please give patient age and explain:  
\_\_\_\_\_

5. Unique clinical indication supported by FDA approval or peer reviewed literature. Please explain and provide a general reference:  
\_\_\_\_\_

6. Unacceptable clinical risk associated with therapeutic change. Please explain:  
\_\_\_\_\_  
\_\_\_\_\_

Signature of Prescriber: \_\_\_\_\_ Date: \_\_\_\_\_

**(Prescriber Signature Mandatory)**

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.